Ian J Jacobs

List of Publications by Year
in descending order

188 papers	16,769 citations	19657 61 h-index	15732 125 g-index
192 all docs	192 docs citations	192 times ranked	17160 citing authors

#	Article	IF	Citations
1	Epigenetic stem cell signature in cancer. Nature Genetics, 2007, 39, 157-158.	21.4	1,023
2	Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer. Cancer Research, 2004, 64, 5882-5890.	0.9	884
3	Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet, The, 2016, 387, 945-956.	13.7	791
4	Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Research, 2010, 20, 440-446.	5.5	740
5	Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology, The, 2009, 10, 327-340.	10.7	738
6	The CA 125 tumour-associated antigen: a review of the literature. Human Reproduction, 1989, 4, 1-12.	0.9	675
7	Screening for ovarian cancer: a pilot randomised controlled trial. Lancet, The, 1999, 353, 1207-1210.	13.7	545
8	Progress and Challenges in Screening for Early Detection of Ovarian Cancer. Molecular and Cellular Proteomics, 2004, 3, 355-366.	3.8	375
9	Diagnostic Performance of Nanoparticle-Enhanced Magnetic Resonance Imaging in the Diagnosis of Lymph Node Metastases in Patients With Endometrial and Cervical Cancer. Journal of Clinical Oncology, 2005, 23, 2813-2821.	1.6	327
10	Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet, The, 2021, 397, 2182-2193.	13.7	313
11	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	311
12	An Epigenetic Signature in Peripheral Blood Predicts Active Ovarian Cancer. PLoS ONE, 2009, 4, e8274.	2.5	291
13	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	21.4	276
14	PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. International Journal of Cancer, 2001, 91, 22-26.	5.1	270
15	Contribution of Germline Mutations in the <i>RAD51B</i>, <i>RAD51C</i>, and <i>RAD51D</i> Genes to Ovarian Cancer in the Population. Journal of Clinical Oncology, 2015, 33, 2901-2907.	1.6	266
16	Development of a Multimarker Assay for Early Detection of Ovarian Cancer. Journal of Clinical Oncology, 2010, 28, 2159-2166.	1.6	246
17	Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal Women. Journal of Clinical Oncology, 2003, 21, 206s-210.	1.6	219
18	Prospective Study Using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer. Journal of Clinical Oncology, 2005, 23, 7919-7926.	1.6	218

#	Article	IF	Citations
19	MULTIMODAL APPROACH TO SCREENING FOR OVARIAN CANCER. Lancet, The, 1988, 331, 268-271.	13.7	213
20	p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet, The, 1998, 352, 871-872.	13.7	187
21	Molecular Evidence Linking Primary Cancer of the Fallopian Tube to BRCA1 Germline Mutations. Gynecologic Oncology, 2000, 76, 45-50.	1.4	186
22	Characterization of Adnexal Mass Lesions on MR Imaging. American Journal of Roentgenology, 2003, 180, 1297-1304.	2.2	186
23	Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncology, The, 2011, 12, 38-48.	10.7	176
24	Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. Lancet, The, 2001, 357, 15-20.	13.7	169
25	Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Journal of Clinical Oncology, 2015, 33, 2062-2071.	1.6	166
26	Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ: British Medical Journal, 1996, 313, 1355-1358.	2.3	164
27	Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection. Clinical Cancer Research, 2015, 21, 622-631.	7.0	158
28	Preoperative Sensitivity and Specificity for Early-Stage Ovarian Cancer When Combining Cancer Antigen CA-125II, CA 15-3, CA 72-4, and Macrophage Colony-Stimulating Factor Using Mixtures of Multivariate Normal Distributions. Journal of Clinical Oncology, 2004, 22, 4059-4066.	1.6	156
29	Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. Journal of Clinical Oncology, 2017, 35, 1411-1420.	1.6	148
30	Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial. Journal of the National Cancer Institute, 2015, 107, 379.	6.3	146
31	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Medicine, 2015, 7, 108.	8.2	138
32	Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development. PLoS Medicine, 2013, 10, e1001551.	8.4	135
33	Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History–Based Testing. Journal of the National Cancer Institute, 2015, 107, 380.	6.3	135
34	Preanalytic Influence of Sample Handling on SELDI-TOF Serum Protein Profiles. Clinical Chemistry, 2007, 53, 645-656.	3.2	131
35	Epigenotyping in Peripheral Blood Cell DNA and Breast Cancer Risk: A Proof of Principle Study. PLoS ONE, 2008, 3, e2656.	2.5	131
36	Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. BMJ: British Medical Journal, 2008, 337, a2079-a2079.	2.3	128

#	Article	IF	Citations
37	The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. BJOG: an International Journal of Obstetrics and Gynaecology, 1993, 100, 927-931.	2.3	127
38	Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. Journal of Pathology, 2003, 201, 544-554.	4.5	127
39	Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule. Journal of Clinical Oncology, 2013, 31, 49-57.	1.6	126
40	Screening Based on the Risk of Cancer Calculation From Bayesian Hierarchical Changepoint and Mixture Models of Longitudinal Markers. Journal of the American Statistical Association, 2001, 96, 429-439.	3.1	125
41	CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. Gynecologic Oncology, 2007, 104, 508-515.	1.4	122
42	Role of MR Imaging in the Selection of Patients with Early Cervical Carcinoma for Fertility-preserving Surgery: Initial Experience. Radiology, 1999, 212, 395-399.	7.3	121
43	The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women's Cancer. PLoS Genetics, 2012, 8, e1002517.	3.5	111
44	MR Imaging of Carcinoma of the Vulva. American Journal of Roentgenology, 2002, 178, 373-377.	2.2	102
45	*HOXA11* DNA methylation—A novel prognostic biomarker in ovarian cancer. International Journal of Cancer, 2008, 123, 725-729.	5.1	97
46	Combinations of Multiple Serum Markers Are Superior to Individual Assays for Discriminating Malignant from Benign Pelvic Masses. Gynecologic Oncology, 1995, 59, 111-116.	1.4	96
47	Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecologic Oncology, 2007, 107, 526-531.	1.4	96
48	Microarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian Cancer. Journal of Proteome Research, 2013, 12, 1408-1418.	3.7	96
49	Recent developments in ovarian cancer screening. Current Opinion in Obstetrics and Gynecology, 2000, 12, 39-42.	2.0	95
50	*BRCA1* and *BRCA2* Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark. Clinical Cancer Research, 2008, 14, 3761-3767.	7.0	92
51	Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. British Journal of Cancer, 2017, 116, 501-508.	6.4	86
52	Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer. Cancer Research, 2007, 67, 3027-3035.	0.9	78
53	Senescent Fibroblasts Promote Neoplastic Transformation of Partially Transformed Ovarian Epithelial Cells in a Three-dimensional Model of Early Stage Ovarian Cancer. Neoplasia, 2010, 12, 317-IN3.	5.3	78
54	Contribution of *BRCA1* and *BRCA2* mutations to inherited ovarian cancer. Human Mutation, 2007, 28, 1207-1215.	2.5	76

#	ARTICLE	IF	CITATIONS
55	Two fetal antigens (FA-1 and FA-2) and endometrial proteins (PP12 and PP14) isolated from amniotic fluid; preliminary observations in fetal and maternal tissues. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1988, 29, 73-85.	1.1	72
56	Cell growth regulation in epithelial ovarian cancer. Cancer, 1993, 71, 1597-1601.	4.1	72
57	Combination of Multiple Serum Markers Using an Artificial Neural Network to Improve Specificity in Discriminating Malignant from Benign Pelvic Masses. Gynecologic Oncology, 1999, 73, 56-61.	1.4	71
58	Screening for Ovarian Cancer. Clinical Obstetrics and Gynecology, 2006, 49, 433-447.	1.1	69
59	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. Clinical Cancer Research, 2016, 22, 1734-1743.	7.0	69
60	The clonal evolution of metastases from primary serous epithelial ovarian cancers. International Journal of Cancer, 2009, 124, 1579-1586.	5.1	68
61	Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 165-169.	2.3	64
62	Single Nucleotide Polymorphisms in the *TP53* Region and Susceptibility to Invasive Epithelial Ovarian Cancer. Cancer Research, 2009, 69, 2349-2357.	0.9	63
63	Improved early detection of ovarian cancer using longitudinal multimarker models. British Journal of Cancer, 2020, 122, 847-856.	6.4	60
64	HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study. International Journal of Cancer, 2009, 125, 2214-2218.	5.1	59
65	Prevention of ovarian cancer: a survey of the practice of prophylactic oophorectomy by fellows and members of the Royal College of Obstetricians and Gynaecologists. BJOG: an International Journal of Obstetrics and Gynaecology, 1989, 96, 510-515.	2.3	58
66	Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. Journal of Medical Genetics, 2014, 51, 108-113.	3.2	58
67	Tagging Single Nucleotide Polymorphisms in the BRIP1 Gene and Susceptibility to Breast and Ovarian Cancer. PLoS ONE, 2007, 2, e268.	2.5	54
68	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. International Journal of Cancer, 2011, 128, 2063-2074.	5.1	54
69	A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome Medicine, 2014, 6, 47.	8.2	53
70	A risk prediction algorithm for ovarian cancer incorporating *BRCA1, BRCA2*, common alleles and other familial effects. Journal of Medical Genetics, 2015, 52, 465-475.	3.2	52
71	Serum Peptide Profiling using MALDI Mass Spectrometry. Proteomics, 2007, 7, 77-89.	2.2	51
72	Predictive Value of Symptoms for Ovarian Cancer: Comparison of Symptoms Reported by Questionnaire, Interview, and General Practitioner Notes. Journal of the National Cancer Institute, 2012, 104, 114-124.	6.3	49

#	Article	IF	Citations
73	Cancer–associated autoantibodies to MUC1 and MUC4—A blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. International Journal of Cancer, 2014, 134, 2180-2188.	5.1	49
74	Molecular evidence of a common clonal origin and subsequent divergent clonal evolution in vulval intraepithelial neoplasia, vulval squamous cell carcinoma and lymph node metastases. International Journal of Cancer, 2002, 99, 549-554.	5.1	47
75	MSI-low, a real phenomenon which varies in frequency among cancer types. Journal of Pathology, 2003, 201, 389-394.	4.5	47
76	Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clinical Cancer Research, 2017, 23, 5912-5922.	7.0	47
77	A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. British Journal of Cancer, 2017, 117, 666-674.	6.4	47
78	Low frequency ofBRAFandCDKN2Amutations in endometrial cancer. International Journal of Cancer, 2005, 115, 930-934.	5.1	46
79	Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. Oncotarget, 2017, 8, 3811-3825.	1.8	45
80	A Molecular Genetic and Statistical Approach for the Diagnosis of Dual-Site Cancers. Journal of the National Cancer Institute, 2004, 96, 1441-1446.	6.3	44
81	Screening for ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 469-482.	2.8	43
82	Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. BMJ: British Medical Journal, 2018, 362, k2644.	2.3	43
83	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Human Molecular Genetics, 2009, 18, 2297-2304.	2.9	42
84	Predicting Clinical Outcome in Patients Diagnosed with Synchronous Ovarian and Endometrial Cancer. Clinical Cancer Research, 2008, 14, 5840-5848.	7.0	41
85	Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. Proteomics - Clinical Applications, 2014, 8, 982-993.	1.6	41
86	Protein Z: A putative novel biomarker for early detection of ovarian cancer. International Journal of Cancer, 2016, 138, 2984-2992.	5.1	41
87	Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. Trials, 2011, 12, 61.	1.6	40
88	In vitro three-dimensional modeling of fallopian tube secretory epithelial cells. BMC Cell Biology, 2013, 14, 43.	3.0	40
89	Common Variants in RB1 Gene and Risk of Invasive Ovarian Cancer. Cancer Research, 2006, 66, 10220-10226.	0.9	39
90	Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population. Clinical Cancer Research, 2018, 24, 4726-4733.	7.0	39

#	Article	IF	Citations
91	Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clinical Cancer Research, 2002, 8, 138-43.	7.0	39
92	Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. BJOG: an International Journal of Obstetrics and Gynaecology, 1993, 100, 1120-1124.	2.3	38
93	Microcell-Mediated Chromosome Transfer Identifies EPB41L3 as a Functional Suppressor of Epithelial Ovarian Cancers. Neoplasia, 2010, 12, 579-IN18.	5.3	38
94	Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). Archives of Gynecology and Obstetrics, 2012, 286, 1555-1562.	1.7	38
95	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. Journal of Medical Genetics, 2018, 55, 546-554.	3.2	38
96	Ovarian cancer screening in the general population. Current Opinion in Obstetrics and Gynecology, 2001, 13, 61-64.	2.0	36
97	Decline in use of hormone therapy among postmenopausal women in the United Kingdom. Menopause, 2007, 14, 462-467.	2.0	36
98	Modelling genetic and clinical heterogeneity in epithelial ovarian cancers. Carcinogenesis, 2011, 32, 1540-1549.	2.8	36
99	Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. Endocrine-Related Cancer, 2012, 19, 137-147.	3.1	36
100	Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 1069-1074.	2.3	33
101	Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. Journal of Medical Genetics, 2022, 59, 632-643.	3.2	33
102	The Effects of Common Genetic Variants in Oncogenes on Ovarian Cancer Survival. Clinical Cancer Research, 2008, 14, 5833-5839.	7.0	32
103	A well‐characterised peak identification list of MALDI MS profile peaks for human blood serum. Proteomics, 2010, 10, 3388-3392.	2.2	32
104	Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. British Journal of Cancer, 2019, 121, 483-489.	6.4	32
105	Peptides Generated Ex Vivo from Serum Proteins by Tumor-Specific Exopeptidases Are Not Useful Biomarkers in Ovarian Cancer. Clinical Chemistry, 2010, 56, 262-271.	3.2	31
106	A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. Laboratory Investigation, 2004, 84, 923-931.	3.7	30
107	Clinical Value of Immunohistochemically Detected Lymphovascular Space Invasion in Early Stage Cervical Carcinoma. Annals of Surgical Oncology, 2008, 15, 2581-2588.	1.5	30
108	Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. Journal of Clinical Epidemiology, 2011, 64, 525-530.	5.0	30

#	Article	IF	Citations
109	Ovarian cancer symptoms, routes to diagnosis and survival â€" Population cohort study in the â€˜no screenâ€™ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecologic Oncology, 2020, 158, 316-322.	1.4	29
110	High-Risk Premenopausal Women's Experiences of Undergoing Prophylactic Oophorectomy: A Descriptive Study. Genetic Testing and Molecular Biomarkers, 2004, 8, 148-156.	1.7	28
111	Screening for Familial Ovarian Cancer: The Need for Well-Designed Prospective Studies. Journal of Clinical Oncology, 2005, 23, 5443-5445.	1.6	28
112	Ovarian cancer screening in the general population. Ultrasound in Obstetrics and Gynecology, 2000, 15, 350-353.	1.7	26
113	Comparative Genomic Hybridization of Microdissected Familial Ovarian Carcinoma: Two Deleted Regions on Chromosome 15q Not Previously Identified in Sporadic Ovarian Carcinoma. Laboratory Investigation, 2001, 81, 1363-1370.	3.7	25
114	Significance of PTEN alterations in endometrial carcinoma: A population-based study of mutations, promoter methylation and PTEN protein expression. International Journal of Oncology, 2004, 25, 1615.	3.3	25
115	Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy. Menopause, 2015, 22, 384-390.	2.0	25
116	Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses. American Journal of Obstetrics and Gynecology, 2020, 222, 56.e1-56.e17.	1.3	25
117	Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. Current Opinion in Obstetrics and Gynecology, 2009, 21, 31-38.	2.0	23
118	Polymorphism in the <i>GALNT1</i> Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women: The Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 600-604.	2.5	23
119	Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. International Journal of Cancer, 2000, 89, 519-523.	5.1	22
120	High frequency of loss of heterozygosity in vulval intraepithelial neoplasia (VIN) is associated with invasive vulval squamous cell carcinoma (VSCC). International Journal of Cancer, 2001, 94, 896-900.	5.1	22
121	Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset. BioMed Research International, 2015, 2015, 1-6.	1.9	22
122	Survival analysis in familial ovarian cancer, a case control study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2001, 98, 219-223.	1.1	21
123	Clinical Value of Immunohistochemically Detected Lymphatic and Vascular Invasions in Clinically Staged Endometrioid Endometrial Cancer. International Journal of Gynecological Cancer, 2009, 19, 1074-1079.	2.5	21
124	Molecular approaches to prevention and detection of epithelial ovarian cancer. Journal of Cellular Biochemistry, 1995, 59, 219-222.	2.6	20
125	Ascites and a Raised Serum Ca 125â€"Confusing Combination. Journal of the Royal Society of Medicine, 2001, 94, 581-582.	2.0	20
126	Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish â€˜MALOVAâ€™ ovarian cancer study. Pathology, 2008, 40, 487-492.	0.6	20

#	Article	IF	Citations
127	The UKCTOCS Experience—Reasons for Hope?. International Journal of Gynecological Cancer, 2012, 22, S18-S20.	2.5	20
128	Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis. Menopause, 2019, 26, 1100-1009.	2.0	20
129	No Evidence Exists for Methylation Inactivation of thep16Tumor Suppressor Gene in Ovarian Carcinogenesis. Gynecologic Oncology, 1998, 68, 14-17.	1.4	19
130	Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer From the Danish "MALOVA"Ovarian Cancer Study. Gynecologic Oncology, 2007, 106, 318-324.	1.4	19
131	Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer, 1995, 76, 1615-1620.	4.1	18
132	Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. Cancers, 2020, 12, 1931.	3.7	18
133	Non-surgical aspects of ovarian cancer. Lancet, The, 1994, 343, 335-340.	13.7	17
134	Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. Cancer, 1999, 85, 2068-2072.	4.1	17
135	Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Human Molecular Genetics, 2009, 18, 1869-1878.	2.9	17
136	Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Cancer Prevention Research, 2019, 12, 391-400.	1.5	17
137	OVX1 Radioimmunoassay Results Are Dependent on the Method of Sample Collection and Storage. Clinical Chemistry, 1999, 45, 692-694.	3.2	16
138	Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis. Gynecologic Oncology, 2003, 91, 218-225.	1.4	16
139	Familial ovarian cancer screening. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2006, 20, 321-338.	2.8	16
140	Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas. Apmis, 2008, 116, 400-409.	2.0	16
141	Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS). Steroids, 2016, 110, 62-69.	1.8	16
142	A quantitative performance study of two automatic methods for the diagnosis of ovarian cancer. Biomedical Signal Processing and Control, 2018, 46, 86-93.	5.7	16
143	The *Sine Qua Non* of Discovering Novel Biomarkers for Early Detection of Ovarian Cancer: Carefully Selected Preclinical Samples. Cancer Prevention Research, 2011, 4, 299-302.	1.5	15
144	Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMJ Open, 2014, 4, e004421.	1.9	15

#	Article	IF	Citations
145	Conformal predictors in early diagnostics of ovarian and breast cancers. Progress in Artificial Intelligence, 2012, 1, 245-257.	2.4	14
146	Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound in Obstetrics and Gynecology, 2013, 42, 472-477.	1.7	14
147	Can Ovarian Cancer Screening Save Lives? The Question Remains Unanswered. Obstetrics and Gynecology, 2011, 118, 1209-1211.	2.4	13
148	Change-point of multiple biomarkers in women with ovarian cancer. Biomedical Signal Processing and Control, 2017, 33, 169-177.	5.7	13
149	Novel risk models for early detection and screening of ovarian cancer. Oncotarget, 2017, 8, 785-797.	1.8	13
150	Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. , 1999, 85, 2068-2072.		12
151	Withdrawal from familial ovarian cancer screening for surgery: Findings from a psychological evaluation study (PsyFOCS). Gynecologic Oncology, 2012, 124, 158-163.	1.4	12
152	Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma. Cancer, 2004, 100, 2387-2395.	4.1	11
153	Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells. International Journal of Cancer, 2009, 124, 1037-1044.	5.1	11
154	Genetic screening for gynecological cancer: where are we heading?. Future Oncology, 2016, 12, 207-220.	2.4	11
155	Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health, 2017, 17, 603.	2.9	11
156	Patterns in the incidence of age-related ovarian cancer in South East England 1967-1996. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 1094-1096.	2.3	10
157	Ovarian cancer screening. British Journal of Hospital Medicine, 2002, 63, 210-213.	0.2	10
158	Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening. International Journal of Gynecological Cancer, 2015, 25, 1519-1525.	2.5	10
159	Impact of a decision aid about stratified ovarian cancer risk-management on women's knowledge and intentions: a randomised online experimental survey study. BMC Public Health, 2017, 17, 882.	2.9	10
160	Final results of 4-monthly screening in the UK Familial Ovarian Cancer Screening Study (UKFOCSS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	10
161	Increased Mortality in Postmenopausal Women with Serum CA125 Elevation. Gynecologic Oncology, 1999, 73, 242-246.	1.4	9
162	Socioeconomic indicators of health inequalities and female mortality: a nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health, 2015, 15, 253.	2.9	9

#	Article	IF	Citations
163	Multiprobabilistic prediction in early medical diagnoses. Annals of Mathematics and Artificial Intelligence, 2015, 74, 203-222.	1.3	9
164	Screening for theBRCA1-ins6kbEx13mutation: potential for misdiagnosis. Human Mutation, 2007, 28, 525-526.	2.5	8
165	Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMJ Open, 2014, 4, e005400-e005400.	1.9	8
166	Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). PLoS ONE, 2016, 11, e0165539.	2.5	8
167	The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT. British Journal of Cancer, 2017, 116, 1111-1117.	6.4	8
168	Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMJ Open, 2017, 7, e011822.	1.9	8
169	ESGO statement on cervical cancer vaccination: August 2007. International Journal of Gynecological Cancer, 2007, 17, 1183-1185.	2.5	7
170	The 14q32 maternally imprinted locus is a major source of longitudinally stable circulating microRNAs as measured by small RNA sequencing. Scientific Reports, 2019, 9, 15787.	3.3	7
171	Completeness and accuracy of national cancer and death registration for outcome ascertainment in trialsâ€"an ovarian cancer exemplar. Trials, 2021, 22, 88.	1.6	7
172	Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Cancers, 2021, 13, 858.	3.7	6
173	Socioeconomic Status and Ovarian Cancer Stage at Diagnosis: A Study Nested Within UKCTOCS. Diagnostics, 2020, 10, 89.	2.6	5
174	Multiprobabilistic Venn Predictors with Logistic Regression. International Federation for Information Processing, 2012, , 224-233.	0.4	5
175	SCREENING FOR EARLY OVARIAN CANCER. Lancet, The, 1988, 332, 171-172.	13.7	4
176	Screening for ovarian cancer. Lancet, The, 1999, 354, 510.	13.7	4
177	UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. Trials, 2021, 22, 173.	1.6	4
178	Distribution of Microsatellite Instability in Danish Ovarian Tumor Patients and the Prognostic Value in Ovarian Cancer Patients. Oncology Research, 2008, 17, 43-49.	1.5	4
179	The value of CA 125 serum assay in the management of ovarian cancer. Commentary. BJOG: an International Journal of Obstetrics and Gynaecology, 1987, 94, 819-820.	2.3	3
180	Screening for familial ovarian cancer. , 2002, , 220-234.		3

#	Article	IF	Citations
181	Screening and Diagnosis of Ovarian Cancer in the General Population. , 2004, , 355-368.		3
182	Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 110-118.	2.3	2
183	CA125 and Other Tumor Markers in Screening and Monitoring of Ovarian Cancer. , 2003, , 193-200.		2
184	Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). F1000Research, 2018, 7, 1241.	1.6	2
185	Registration of ovarian cancer in England and Wales. British Journal of Cancer, 2000, 83, 279-279.	6.4	1
186	Management of familial ovarian cancer. , 2002, , 275-285.		1
187	Ovarian Cancer Screening. , 2006, , 47-68.		1
188	Screening for Ovarian Cancer. , 0, , 144-150.		0